3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Classical hematology
1
Conditions
Leukemia, Myeloid, Acute
38
Myelodysplastic Syndromes
9
Leukemia
6
Leukemia, Monocytic, Acute
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Myeloproliferative Disorders
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myelomonocytic, Acute
2
Burkitt Lymphoma
2
Thrombocythemia, Essential
1
Recurrence
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Megakaryoblastic, Acute
1
Leukemia, Lymphoid
1
Leukemia, Erythroblastic, Acute
1
Leukemia, Biphenotypic, Acute
1
Hodgkin Disease
1
Congenital Abnormalities
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
fludarabine phosphate
50
Cyclophosphamide
50
Mycophenolic Acid
36
Cyclosporine
33
Busulfan
33
Whole-Body Irradiation
32
Peripheral Blood Stem Cell Transplantation
31
Antilymphocyte Serum
24
fludarabine
21
Cord Blood Stem Cell Transplantation
21
Tacrolimus
20
Cytarabine
19
Filgrastim
18
Melphalan
17
Radiotherapy
15
Methylprednisolone
13
Methotrexate
13
Thiotepa
10
Granulocyte Colony-Stimulating Factor
10
Etoposide
9
Cyclosporins
7
Azacitidine
7
thymoglobulin
5
sargramostim
5
Idarubicin
5
Clofarabine
5
Arsenic Trioxide
5
Transplantation
4
Sirolimus
4
Gemtuzumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Anemia, Refractory, with Excess of Blasts
×
CPX-351
×
Clear all
NCT05829434
2024-02-12
MAGROLIC
University of Leipzig
Phase 2
Withdrawn